Comparative Pharmacology
Head-to-head clinical analysis: DEPINAR versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPINAR versus H CORT.
DEPINAR vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depinar is a formulation of estradiol valerate and dihydroxyprogesterone acetophenide, a synthetic progestin. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, activating gene transcription and exerting estrogenic effects. Dihydroxyprogesterone acetophenide is a progestogen that binds to progesterone receptors, inducing endometrial transformation and inhibiting gonadotropin release.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
2.5–5 mg orally once daily, max 10 mg/day
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category C
Category C
Corticosteroid
Corticosteroid